Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor …
BL Rapoport, K Jordan, JA Boice, A Taylor… - Supportive Care in …, 2010 - Springer
Purpose Aprepitant was shown previously to be effective for prevention of chemotherapy-
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt, R de Wit… - Supportive Care in …, 2006 - Springer
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
RM Navari - Expert Opinion on Investigational Drugs, 2007 - Taylor & Francis
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common adverse
event associated with cancer treatment. Updated anti-emetic guidelines were published in …
event associated with cancer treatment. Updated anti-emetic guidelines were published in …
[HTML][HTML] Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists
SM Bošnjak, RJ Gralla, L Schwartzberg - Supportive Care in Cancer, 2017 - Springer
Chemotherapy-induced nausea (CIN) has a significant negative impact on the quality of life
of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT 3) receptor antagonists (RAs) …
of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT 3) receptor antagonists (RAs) …
Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types
MS Aapro, HJ Schmoll, F Jahn, AD Carides… - Cancer treatment …, 2013 - Elsevier
Chemotherapy regimens differ according to the tumor type being treated and are associated
with varying degrees of emetogenic potential. Since the distribution of risk factors for …
with varying degrees of emetogenic potential. Since the distribution of risk factors for …
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
L Annemans, D Strens, E Lox, C Petit… - Supportive Care in …, 2008 - Springer
Objectives Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse
effect of cancer chemotherapy which may increase morbidity, reduce quality of life and …
effect of cancer chemotherapy which may increase morbidity, reduce quality of life and …
[HTML][HTML] The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M Aapro, A Molassiotis, M Dicato, I Peláez… - Annals of oncology, 2012 - Elsevier
Background While guidelines for preventing chemotherapy-induced nausea and vomiting
(CINV) are widely available, clinical uptake of guidelines remains low. Our objective was to …
(CINV) are widely available, clinical uptake of guidelines remains low. Our objective was to …
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
V Piechotta, A Adams, M Haque… - Cochrane Database …, 2021 - cochranelibrary.com
Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …
[HTML][HTML] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant …
L Zhang, S Lu, J Feng, A Dechaphunkul, J Chang… - Annals of …, 2018 - Elsevier
Background Co-administration of multiple antiemetics that inhibit several molecular
pathways involved in emesis is required to optimize chemotherapy-induced nausea and …
pathways involved in emesis is required to optimize chemotherapy-induced nausea and …
[HTML][HTML] Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K Jordan, F Jahn, M Aapro - Annals of Oncology, 2015 - Elsevier
The prevention of chemotherapy-induced nausea and vomiting (CINV) has been
revolutionized over the past 25 years. Guideline-based treatment means that vomiting can …
revolutionized over the past 25 years. Guideline-based treatment means that vomiting can …